Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-517-7330
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees14
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions
What is Cyclacel Pharmaceuticals' stock symbol?
Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."
When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?
Shares of Cyclacel Pharmaceuticals reverse split on the morning of Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.
How were Cyclacel Pharmaceuticals' earnings last quarter?
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) posted its quarterly earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. View Cyclacel Pharmaceuticals' Earnings History.
When is Cyclacel Pharmaceuticals' next earnings date?
What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cyclacel Pharmaceuticals.
Has Cyclacel Pharmaceuticals been receiving favorable news coverage?
News coverage about CYCC stock has trended somewhat negative on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cyclacel Pharmaceuticals earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Cyclacel Pharmaceuticals.
Are investors shorting Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals saw a decline in short interest in September. As of September 30th, there was short interest totalling 324,800 shares, a decline of 21.1% from the August 30th total of 411,600 shares. Based on an average daily trading volume, of 73,200 shares, the days-to-cover ratio is presently 4.4 days. Approximately 1.9% of the company's stock are short sold. View Cyclacel Pharmaceuticals' Current Options Chain.
Who are some of Cyclacel Pharmaceuticals' key competitors?
Some companies that are related to Cyclacel Pharmaceuticals include Sierra Oncology (SRRA), Intec Pharma (NTEC), Ceapro (CRPOF), Acerus Pharmaceuticals (TRLPF), OncoSec Medical (ONCS), Provectus Biopharmaceuticals (PVCT), ProPhase Labs (PRPH), Aytu Bioscience (AYTU), Mateon Therapeutics (MATN), Pain Therapeutics (PTIE), Cassava Sciences (SAVA), Kazia Therapeutics (KZIA), Seelos Therapeutics (SEEL), KemPharm (KMPH) and AEterna Zentaris (AEZS).
What other stocks do shareholders of Cyclacel Pharmaceuticals own?
Who are Cyclacel Pharmaceuticals' key executives?
Cyclacel Pharmaceuticals' management team includes the folowing people:
- Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)
- Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)
- Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)
- Ms. Gill Christie, Director of HR (Age 62)
- Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75)
How do I buy shares of Cyclacel Pharmaceuticals?
Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cyclacel Pharmaceuticals' stock price today?
One share of CYCC stock can currently be purchased for approximately $0.37.
How big of a company is Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals has a market capitalization of $6.40 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-7,290,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Cyclacel Pharmaceuticals employs 14 workers across the globe.View Additional Information About Cyclacel Pharmaceuticals.
What is Cyclacel Pharmaceuticals' official website?
How can I contact Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]
MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
